Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Disease Areas › Cancer › Verastem Oncology Launches Phase II Trial of MEK, Pan-RAF Inhibitor in Ovarian Cancer

Verastem Oncology Launches Phase II Trial of MEK, Pan-RAF Inhibitor in Ovarian Cancer

Nov 30, 2020
|
staff reporter

NEW YORK – Verastem Oncology on Monday announced the launch of a Phase II clinical trial of its investigational MEK and pan-RAF inhibitor, VS-6766, as a treatment for recurrent, low-grade serous ovarian cancer patients, including those harboring KRAS mutations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Featured Webinar

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Featured Webinar

Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

What's Popular?

In Cancer

  1. In Brief This Week: Gilead Sciences, Atossa Therapeutics, Karmanos Cancer Institute

  2. Immunocore's Tebentafusp Prolongs Survival in Uveal Melanoma Patients, AACR Study Shows

    Premium

  3. Gene Expression Score IDs PD-1/PD-L1 Immune Checkpoint Inhibitor Resistance in Bladder Cancers

  4. Celcuity Licenses PI3K/mTOR Inhibitor from Pfizer, Enters $25M Debt Financing Agreement

  5. With Support From Lawmakers, WGS Becoming More Accessible to Netherlands' Cancer Patients

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.